Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Analyzed 45 papers and selected 3 impactful articles.
Selected Articles
1. Group B streptococcal disease in infants 0-3 months in The Netherlands, 1987-2023: a nationwide genomic and epidemiological surveillance study.
Over 37 years of nationwide surveillance in the Netherlands identified 2,212 infant GBS sepsis/meningitis episodes with rising incidence driven by sepsis. Serotype III and CC17 predominated and increased over time. Modeling suggests maternal GBS6 and GBS‑AlpN vaccines could cover 97% and 99% of strains, respectively.
Impact: Defines contemporary burden and molecular epidemiology of infant GBS sepsis and quantifies potential prevention by maternal vaccines, directly informing immunization policy.
Clinical Implications: Supports prioritizing maternal GBS vaccination programs and heightened surveillance for CC17-associated disease; guides empiric management and anticipates vaccine impact on serotype distribution.
Key Findings
- Incidence increased from 0.19 (1987) to 0.57 per 1000 live births (2023), p<0.0001, driven by sepsis.
- Serotype III accounted for 61% of isolates; Ia 18%, II 6%.
- CC17 was the most common clonal complex (41%) and rose from 29% to 49% across decades.
- Estimated vaccine coverage: 97% for GBS6 and 99% for GBS‑AlpN.
Methodological Strengths
- Nationwide, long-term surveillance with large sample size (n=2212).
- Integrated serotyping and whole-genome sequencing (MLST) to track clonal dynamics.
- Direct estimation of maternal vaccine strain coverage.
Limitations
- Observational design limits causal inference about incidence drivers.
- Potential ascertainment changes over decades; sequencing not available for all isolates.
Future Directions: Evaluate real-world effectiveness and serotype replacement after maternal GBS vaccination; enhanced genomic surveillance for emergent lineages.
BACKGROUND: Group B METHODS: This nationwide observational study identified infants aged 0-89 days with GBS culture-positive sepsis or meningitis between July 1987 and June 2024, through Dutch surveillance. Serotype was determined by latex agglutination. Whole-genome sequencing determined the clonal complex (CC) using multi-locus sequence typing (MLST) and identified virulence factors associated with meningitis. Strain coverage by the maternal vaccines GBS6 and GBS-AlpN were analysed. FINDINGS: 2212 episodes were identified; 1307 (59%) early onset disease (0-6 days) and 905 (41%) late onset disease (7-89 days). Mean annual incidence was 0·33 per 1000 live births and significantly increased from 0·19 in 1987 to 0·57 in 2023 due to an increase in sepsis cases (p < 0·0001). Serotype data was available for 2163 (98%) of 2212 isolates, of which serotype III was most common (1316/2163; 61%), followed by Ia (383/2163; 18%) and II (123/2163; 6%). MLST data was available for 1723 (78%) isolates; CC17 was most common (705/1723; 41%). CC17 increased from 29% (90/308) in 1987-1996 to 49% (262/538) in 2014-2023 (p < 0·0001). 97% (2095/2163) of cases would be covered by the GBS6 vaccine, and 99% (1709/1723) by GBS-AlpN. INTERPRETATION: GBS disease is still increasing in the Netherlands. The GBS6 and GBS-AlpN vaccines would potentially prevent >96% of cases. FUNDING: Netherlands Organisation for Health Research and Development (ZonMW) and ItsME foundation.
2. PPARγ Variant rs10865710 and Mortality in Pediatric Septic Shock Stratified by Corticosteroid Exposure.
In 381 children with septic shock, the PPARγ rs10865710 variant was associated with higher 28-day mortality, particularly among those receiving systemic corticosteroids (adjusted OR 5.85). No effect was seen for rs1801282, and eQTL data suggested possible differences in glucocorticoid receptor signaling.
Impact: Highlights a pharmacogenomic signal linking a common PPARγ variant to differential harm from corticosteroids in pediatric septic shock, enabling potential precision-medicine stratification.
Clinical Implications: If validated, genotyping rs10865710 could inform steroid use decisions in pediatric septic shock; careful risk–benefit consideration is warranted when considering corticosteroids in variant carriers.
Key Findings
- rs10865710 carriage associated with higher 28-day mortality (10.2% vs 3.5%, p=0.009).
- Among corticosteroid-treated patients, rs10865710 increased mortality risk (adjusted OR 5.85; 95% CI 1.62–30.44) and hazard of death (HR 5.33; 95% CI 1.43–19.83).
- No association for rs1801282; genotype not linked to baseline risk strata or endotype.
- eQTL subset (n=81) showed no cis effect on PPARγ; trend toward lower NR3C1 expression (p=0.07).
Methodological Strengths
- Multicenter prospective design with prespecified steroid-stratified analyses.
- Robust multivariable logistic and Cox modeling; genetic quality control (HWE).
- Integration of exploratory eQTL analyses.
Limitations
- Observational design limits causal inference and potential treatment-by-indication bias.
- Moderate sample size; eQTL subset was small and underpowered.
- Replication in independent cohorts is lacking.
Future Directions: Independent replication, mechanistic dissection of PPARγ–glucocorticoid receptor cross-talk, and prospective stratified trials to test genotype-guided steroid therapy.
OBJECTIVES: To determine whether genetic variation in peroxisome proliferator-activated receptor gamma (PPARγ) is associated with mortality across corticosteroid exposure strata in pediatric septic shock. DESIGN: Multicenter prospective observational study. SETTING: PICUs at multiple U.S. hospitals. PATIENTS: Children 1 week to 10 years old meeting consensus criteria for septic shock. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Genomic DNA was genotyped for two PPARγ single nucleotide variants (SNVs; rs10865710 and rs1801282) using TaqMan assays. Associations with 28-day mortality were evaluated using multivariable logistic regression and Cox proportional hazards models, with analyses stratified by systemic corticosteroid exposure within 72 hours. In a subset with whole-blood RNA sequencing, expression quantitative trait locus (eQTL) analyses assessed genotype effects on candidate transcripts. Among 381 patients, both SNVs were in Hardy-Weinberg equilibrium. Carriage of the rs10865710 mutant allele was associated with higher 28-day mortality (10.2% vs. 3.5%; p = 0.009), whereas rs1801282 showed no association. In stratified analyses, rs10865710 carriage was associated with increased mortality among corticosteroid-treated patients (adjusted odds ratio, 5.85; 95% CI, 1.62-30.44; p = 0.015) but not corticosteroid-naive patients. Similarly, in stratified Cox models, rs10865710 carriage was associated with increased hazard of death among corticosteroid-treated patients (hazard ratio, 5.33; 95% CI, 1.43-19.83; p = 0.013). Genotype was not associated with established mortality risk strata or transcriptomic endotype. In eQTL analyses (n = 81), rs10865710 carriage was not associated with PPARγ expression; however, a trend toward lower glucocorticoid receptor (NR3C1) expression was noted (p = 0.07). CONCLUSIONS: The intronic PPARγ variant rs10865710 is associated with increased mortality in pediatric septic shock, with the association most apparent among corticosteroid-treated patients. Although no cis-eQTL effect on PPARγ expression was detected, exploratory data suggest potential differences in glucocorticoid receptor signaling. Prospective validation and mechanistic studies are warranted.
3. Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.
A scalable environmental exposure model shows that colonization with soil-derived microbiota drives systemic Treg/IL-10+ programs and protects mice from colitis, metabolic disease, and sepsis, extending health span and lifespan. This provides a more physiologically relevant platform for microbiota–host studies.
Impact: Introduces a practical, reproducible environmental microbiota model that reveals immune mechanisms (Treg/IL-10) conferring sepsis protection, addressing a key translational gap in preclinical research.
Clinical Implications: While preclinical, findings suggest harnessing environmental-like microbial exposures or microbial consortia to induce regulatory immunity as a potential preventive strategy against sepsis and inflammatory comorbidities.
Key Findings
- Developed a scalable, reproducible environmental exposure (ENV) model using soil-derived microbiota.
- Sustained colonization, particularly by Gram-negative bacteria, shifted immunity toward anti-inflammatory programs.
- Expansion of regulatory T cells and IL-10+ innate/adaptive populations was observed.
- Protection against colitis, obesity, diabetes, and sepsis; extension of health span and lifespan.
Methodological Strengths
- Novel, scalable, and cost-effective preclinical model with reproducible colonization.
- Demonstrated protection across multiple disease models including sepsis.
- Mechanistic linkage to Treg and IL-10+ immune pathways.
Limitations
- Mouse model; translational applicability to humans remains uncertain.
- Specific microbial taxa and transferable consortia responsible for protection are not fully defined.
- Duration and dose–response parameters are not detailed in the abstract.
Future Directions: Define protective consortia/taxa, test humanized microbiota and gnotobiotic validations, and evaluate safety and efficacy of translational microbial therapeutics.
Recent years have highlighted the profound influence of the gut microbiota not only on local immunity but also on systemic host physiology. However, the translational potential of findings from preclinical animal models remains limited, in part owing to their microbiomes shaped in the absence of natural environmental cues. To address this gap, we developed a scalable, cost-effective, and reproducible preclinical model of environmental exposure (ENV), in which local soil-derived microbiota colonize laboratory mice. Sustained colonization with environmental microbes, particularly Gram-negative bacteria, was associated with a shift toward local and systemic anti-inflammatory immune responses, supporting the expansion of regulatory T cells (Tregs) and IL-10⁺ innate and adaptive populations. These changes confer protection against colitis, obesity, diabetes, and sepsis, ultimately extending both health span and lifespan. Thus, natural microbial exposure lays the foundation for future studies into microbiota‒host interactions, therapeutic resistance, and the development of more physiologically relevant models for human disease.